Journal
CELL
Volume 184, Issue 16, Pages 4220-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2021.06.020
Keywords
-
Categories
Funding
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [2018-I2M-2-002]
- Wellcome Trust [101122/Z/13/Z, GB-CHC-210183, 090532/Z/09/Z, 203141/Z/16/Z]
- Cancer Research UK [C375/A17721]
- UKRI MRC [MR/N00065X/1]
- MRC [MC_PC_19060, MC_PC_20016]
- Fast Grants
- Mercatus Center for supporting the isolation of human monoclonal antibodies
- Schmidt Futures
- FAPEAM
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [403276/2020-9]
- Inova Fiocruz/Fundacao Oswaldo Cruz [VPPCB-007-FIO-18-2-30]
- NIHR [NIHR300791, WT109965MA, COV19-RECPLAS]
- NIHR Oxford BRC
- UK Research and Innovation
- Coalition for Epidemic Preparedness Innovations
- National Institute for Health Research (NIHR)
- NIHR Oxford Biomedical Research Centre
- Thames Valley and South Midland's NIHR Clinical Research Network
- Red Avenue Foundation
- UKRI
- UK Department of Health and Social Care
- UK Coronavirus Immunology Consortium (UK-CIC)
- Huo Family Foundation
- NIH [U19 I082360]
- Bill & Melinda Gates Foundation [INV-016202]
- MRC [MC_PC_19060, MR/N00065X/1, MC_PC_20016] Funding Source: UKRI
- Bill and Melinda Gates Foundation [INV-016202] Funding Source: Bill and Melinda Gates Foundation
- National Institutes of Health Research (NIHR) [NIHR300791] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B. 1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available